Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CCR1 | P32246 | 3/20 | 0.59 |
| ▸ | CCR5 | P51681 | 3/20 | 0.59 |
| ▸ | CCR8 | P51685 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645424 | 0.98 | KDM4E (0.56) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1515109 | 0.95 | KDM4E (0.59) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL497656 | 0.90 | — | — | |
| SCHEMBL449001 | 0.80 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL5922 | 0.76 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29907716 | 0.76 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29351528 | 0.76 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3711450 | 0.76 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL8655605 | 0.73 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL7909040 | 0.73 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377315-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-04-18 | — | — | US | disclosed |
| WO-2024076614-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024030908-A1 | MULTI-CYCLIC IRAK1 AND IRAK4 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023250431-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-117015380-A | Polycyclic IRAK and flt3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2023-11-07 | — | — | CN | disclosed |
| EP-4267142-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4262802-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-10-25 | — | — | EP | disclosed |
| US-6150532-A | OXAZOLE COMPOUNDS WITH UNSATURATED ACID OR ESTER GROUPS AS ENZYME INHIBITORS | MJALLI ADNAN (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000033836-A1 | 5-MEMBERED HETEROCYCLES FOR THE TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF SELECTINS | ONTOGEN CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034255-A1 | SUBSTITUTED THIAZOLES FOR TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF P-, L- AND E- SELECTIN | ONTOGEN CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5965558-A | 2 OR 2,3-DI((2-CARBOXYETHYLENEARYL)QUINOXALINES; PURIFICATION OF PROTEINS AND GLYCOPROTEINS; UNITS INCLUDING PROTEIN TYROSINE PHOSPHATASES AND PROTEINS WITH SRC-HOMOLOGY-2 DOMAINS; ANTIDIABETICS,-ALLERGENS,-COAGULANTS | ONTOGEN CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0946518-A1 | MODULATORS OF PROTEINS WITH PHOSPHOTYROSINE RECOGNITION UNITS | ONTOGEN CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998027065-A1 | MODULATORS OF PROTEINS WITH PHOSPHOTYROSINE RECOGNITION UNITS | ONTOGEN CORPORATION (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5753687-A | ACRYLATED ARYLIMIDAZOLE DERIVATIVES | ONTOGEN CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | KDM4E 278/4885LMNA 2188/4885CCR1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.